• Algere, A., Diaz Mediavilla, J., San Miguel, J., Martinez, R., Garcia Larana, J., Surenda, A., Lahuerta, J.J., Morales, D., Blade, J., Caballero, D., De la Rubia, J., Escudero, A., Diez-Martin, J.L., Hernander-Navarro, F., Rifon, J., Odriozola, J., Brunet, S., De la Serna, J., Besalduch, J., Vidal, M. J., Solano, C., Leon, A., Sanchez, J.J., Martinez-Chamorro, C. & Fernandez-Ranada, J.M. (1998) Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Bone Marrow Transplantation, 21, 133140.
  • Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. & Laurent, G. (1992) Intensive combined therapy for previously untreated aggressive myeloma. Blood, 79, 11301136.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 9197.
  • Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789793.
  • Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D.H., Siegel, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 5565.
  • Blade, J., Lopez Gullermo, A., Bosch, F., Cervantes, F., Montserrat, E. & Rozman, C. (1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 88, 117121.
  • Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. British Journal of Haematology, 102, 11151123.
  • Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M.T., Bacigalupo, A., Santoro, A., Musso, M., Majolino, I., Boccadoro, M. & Pileri, A. (1999) Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 17, 208215.
  • Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C. & Malpas, J. (1994) High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Journal of Clinical Oncology, 12, 759763.
  • Evans, P.A., Short, M.A., Owen, R.G., Jack, A.S., Forsyth, P.D., Schiach, C.R., Kinsey, S. & Morgan, G.J. (1998) Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 36163627.
  • Gore, M.E., Selby, P.J., Viner, C., Clark, P.I., Meldrum, M., Millar, B., Bell, J., Maitland, J.A., Milan, S. & Judson, I.R. (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, 2, 879882.
  • Guikema, J.E.J., Vellenga. E., Veeneman. J.M., Hovenga. S., Bakkus. M.H.C., Klip. H. & Bos. N.A. (1998) Multiple myeloma related cells in patients undergoing peripheral blood stem cell transplantation. British Journal of Haematology, 104, 748754.
  • Haroussseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H., Caillot, D., Boasson, M. & Abdgrall, J.F. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of French Registry on autologous transplantation in multiple myeloma. Blood, 8, 30773085.
  • Hart, D.N., Schulze, J.L. & Stewaert, A.K. (1999) Presentation of tumour cell antigens. Seminars in Hematology, 36, 2125.
  • Kwak, L.W., Sternas, L.A., Jagannath, S., Barlogie, B. & Munshi, N. (1997) T cell responses elicited by immunisation of multiple myeloma patients with idiotypic M protein plus GM-CSF in remission after autologous transplantation. Blood, 90, 579.
  • Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., Wisloff, F., Brinch, L., Carlson, K., Cerlsson, M., Dahl, I.M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I. & Rodjer, S. (2000) Impact on survival of high does therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood, 95, 711.
  • MacLennan, I.C., Chapman, C., Dunn, J. & Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Councl Working Party for Leukaemia in Adults. Lancet, 25, 200205.
  • Martinelli, G., Terragna, C., Cavo, M., Lemoli, R., Bandini, G., Zamagni, E., Ronconi, S., Tosi, P., Motta, M., Testoni, N., Amabike, M., Ottaviavi, E., Vianelli, N., De Vivo, A. & Tura, S. (1999) Multiple myeloma patients achieving molecular remission after transplantation of hematopoietic cells had a significantly lower elapse rate and higher relapse free survival. Blood, 94, (Abstract1279).
  • McElwain, T.J. & Powles, R.L. (1983) High dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet, ii, 822824.
  • Owen, R.G., Johnson, R.J., Rawstron, A.C., Evans, P.A., Jack, A.S., Smith, G.M., Child, J.A. & Morgan, G.J. (1996) Assessment of IgH PCR strategies in multiple myeloma. Journal of Clinical Pathology, 49, 672675.
  • Powles, R., Raje, N., Milan, S., Millar, B., Shepherd, V., Mehta, J., Singhal, S., Kulkarni, S., Viner, C., Gore, M., Cunningham, D. & Treleaven, J. (1997) Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplantation, 20, 435443.
  • Raje, N., Powles, R., Kullarni, S., Milan, S., Middleton, G., Singhal, S., Mehta, J., Millar, B., Viner, C., Raymond, J., Treleavan, J., Cunningham, D. & Gore, M. (1997) A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology, 97, 153160.
  • Samson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T. & Hamon, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma. Lancet, 2, 882885.
  • Singhal, S., Powles, R., Milan, S., Raje, N., Viner, C., Treleaven, J., Raymond, J., Cunningham, D. & Mehta, J. (1995) Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplantation, 16, 537540.
  • Zent, C.S., Williams, C.S., Tricot, G., Jagannath, S., Siegel, D., Desikan, K.R., Munshi, N., Bracy, D., Barlogie, B. & Butch, A.W. (1998) Oligoclonal bands and Ig Isotype switching in multiple myeloma treated with high dose therapy and hematopoietic cell transplantation. Blood, 91, 35183523.